Navigation Links
Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
Date:7/12/2013

n of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clin
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
2. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
3. Generex Announces Date of Annual Stockholders Meeting
4. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
5. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
6. Generex Secures Commitments for $3.6M Capital Raise
7. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
8. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
9. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
10. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
11. Averica Discovery Announces Winner of First Averica Award for Supercritical Fluid Chromatography (SFC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... MA (PRWEB) July 29, 2014 The ... Library of Congress was recently awarded to Juliana Hillis ... Stoneham, MA, for their project, “From an Egg, Everything: ... among 3,000 final entries for the National History Day ... than 300 historians and educators in Washington, D.C. , ...
(Date:7/29/2014)... 29, 2014 EXpressLO LLC, expert provider ... specimen preparation solutions, has been granted patent number 8,789,826 ... manipulation methods incorporating a unique specimen carrier support grid ... the second company patent for EXpressLO LLC awarded to ... , These complementary patents extend EXpressLO’s portfolio of intellectual ...
(Date:7/28/2014)... DIEGO , July 28, 2014 ... cultivation technologies, today announced the appointment of biotechnology veteran ... of the board of directors. Levine replaces Cynthia ,CJ, ... immediately. She will remain chairman of the company,s board ... on Sapphire Energy,s mission to deliver commercial scale algae-based ...
(Date:7/28/2014)... July 28, 2014 According to ... Market Research "Regenerative Medicine (Bone and Joint) Market ... Tissue Engineering; By Applications - Bone Graft Substitutes, ... - Global Industry Analysis, Size, Share, Growth, Trends ... medicine (bone and joint) market was valued at ...
Breaking Biology Technology:In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
... for Presentation at ASCO, SOUTH SAN FRANCISCO, Calif., May ... it will hold an investor and,analyst briefing in conjunction with ... (ASCO) from 6:00 p.m. to 8:00 p.m. CT,on Monday, June ... PhD, President and Chief Executive Officer -- Michael M. ...
... Mass., May 21 Interleukin Genetics,Inc. (Amex: ... into law of the,Genetic Information Nondiscrimination Act (GINA). ... April 25, 2008, and signed into law by,President ... intended to ensure that individuals are protected,from genetic ...
... Germany, Mai 21, 2008 / b3c newswire ... both leading companies in biopharmaceutical development and ... The cooperation will enable Rentschler Biotechnologie’s clients ... mammalian biopharmaceutical production facilities in Biberach, Germany ...
Cached Biology Technology:Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 2Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 4Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 2Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 3Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim 2Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim 3
(Date:7/27/2014)... has revealed that nicotine and cotinine, a metabolite of ... certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or ... and ultimately ends up in the tobacco smoke. Once ... where it is activated by a variety of enzymes ... revealed that nicotine can partially interfere with the activation ...
(Date:7/27/2014)... can evade treatment by acquiring mutations in the genes ... were once thought to be the only way for ... shown that microorganisms can use a temporary silencing of ... the benefits of drug resistance without the commitment. , ... called Mucor circinelloides, it is likely to be employed ...
(Date:7/27/2014)... patients, scientists have identified more than two dozen ... six that had not been previously reported. The ... partially funded by the National Institutes of Health ... laboratories. , "Unraveling the genetic underpinnings of Parkinson,s ... in this complex disease, and hopefully, may one ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... ice-free summers with intermittent winter sea ice in the Arctic ... conditions - gives a glimpse of how the Arctic is ... past environmental change in the Arctic should help predict its ... 65 million years ago leading up to the extinction of ...
... PHILADELPHIA Researchers from the Centers for Disease Control ... ovarian cancer is influenced by age of menarche and ... suggests that hormonal activity over the course of a ... cancer diagnosis. Results of this study are published in ...
... Environmental Health Perspectives (EHP) co-authored by ... Project on Emerging Nanotechnologies (PEN), focuses on the ... provides an overview of current practices; research findings; ... and possible future directions for nanoremediation. The authors ...
Cached Biology News:Arctic climate under greenhouse conditions in the Late Cretaceous 2Arctic climate under greenhouse conditions in the Late Cretaceous 32 reproductive factors are important predictors of death from ovarian cancer 22 reproductive factors are important predictors of death from ovarian cancer 3Contaminated site remediation: Are nanomaterials the answer? 2